Janssen Vaccines
Janssen Vaccines is a division of Janssen Pharmaceuticals, which is itself a subsidiary of Johnson & Johnson. Janssen Vaccines is focused on the development, production, and marketing of vaccines to prevent and combat infectious diseases.
History[edit | edit source]
Janssen Vaccines was established as Crucell in 2000, following the merger of several biotechnology companies. In 2011, it was acquired by Johnson & Johnson and renamed as Janssen Vaccines.
Research and Development[edit | edit source]
Janssen Vaccines conducts extensive research and development in the field of vaccinology, with a particular focus on diseases such as HIV, Ebola, RSV, and Zika virus. The company's research strategy involves the use of innovative technologies, such as adenovirus-based vectors, to develop novel vaccines.
Products[edit | edit source]
One of the most notable products of Janssen Vaccines is the Janssen COVID-19 Vaccine, also known as Ad26.COV2.S. This vaccine was granted Emergency Use Authorization by the FDA in February 2021 for the prevention of COVID-19 in individuals 18 years of age and older.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
